5 results about "Bifunctional chelator" patented technology

This invention discloses a method for deashing polyolefins based on the synergistic effect of a bifunctional chelating agent and periodic supercritical CO2, belonging to the field of polyolefin material preparation technology. First, a bifunctional chelating agent with both CO2 affinity and metal chelating ability is synthesized. Then, polypropylene material and the chelating agent are placed in a high-pressure reactor, CO2 is injected, and the temperature and pressure are increased to a supercritical state. Under the condition of maintaining the supercritical temperature, the pressure is periodically controlled, causing the pressure to pulsate between high and low pressure, sequentially experiencing a swelling / permeation stage and an expansion / elution stage. After the cycle is completed, the pressure is released, and high-purity polypropylene is obtained after post-treatment. This invention transforms static diffusion mass transfer into forced convection mass transfer through periodic pressure control, achieving deep removal of metal residues with a removal rate as high as 97.14%. The total ash content of the product can be reduced to 5.29 ppm, with no significant impact on the properties of the polypropylene itself. It also features short processing time and significant environmental advantages.

This invention discloses an Evans blue-modified nucleic acid aptamer targeting EpCAM, its preparation method, and its application. The Evans blue-modified nucleic acid aptamer EB-SYL3C is composed of SYL3C, a bifunctional chelating agent, and truncated Evans blue. Using EB-SYL3C as a ligand can prolong the blood circulation half-life of SYL3C, as well as improve tumor uptake and tumor retention time, thereby enabling its application in EpCAM-targeted radionuclide diagnosis or treatment.

This invention relates to the field of nuclear medicine technology, and more particularly to a linker, compound, and radionuclide conjugate targeting prostate-specific membrane antigen (PSMA), and their applications. By linking a linker with a specific structure to a targeting carrier and a targeting ligand, respectively, a compound targeting PSMA is formed, and further labeled with a radionuclide to prepare a radionuclide conjugate. The linker in this invention can effectively enhance the affinity of PSMA ligands, and compounds including these linkers can serve as bifunctional chelating agents, simultaneously enabling the labeling of diagnostic and therapeutic radionuclides, achieving integrated diagnosis and treatment. Furthermore, the radionuclide conjugates constructed from these linkers exhibit good metabolic activity and significantly improved structural stability.

This invention discloses a polypeptide PET probe targeting FDG-negative solid tumors, its preparation method, and its application. It belongs to the fields of tumor diagnosis and nuclear medicine imaging. The polypeptide probe primarily targets the CD44v6 protein, as tumors with low FDG uptake often highly express this important target. Specifically, the bifunctional chelating agent NOA is linked to the optimized targeting polypeptide sequence NRWHEDC, and then radioactive nuclide is used for further processing. 18 F or 68 The Ga labeling and purification steps yielded a radionuclide-labeled peptide probe. This probe preparation method is simple and efficient, suitable for large-scale production. More importantly, it possesses high affinity and specificity, enabling PET to identify FDG-negative solid tumors, facilitating early detection, staging, efficacy evaluation, and recurrence monitoring.

This invention discloses a radiopharmaceutical targeting chondroitin sulfate proteoglycan 4 (CSPG4) with a linear polypeptide and its preparation method. The radiopharmaceutical comprises a CSPG4-targeting polypeptide, a radionuclide, and a bifunctional chelating agent. The radionuclide is labeled with the CSPG4-targeting polypeptide by the bifunctional chelating agent, wherein the targeting polypeptide has a linear structure consisting of 10 or 11 amino acids. This series of radiopharmaceuticals can achieve specific nuclear medicine positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging diagnosis of CSPG4-positive lesions, such as tumors, autoimmune diseases, cardiovascular diseases, and neurodegenerative diseases, in vivo.